Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 ye...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/5872423 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552743074529280 |
|---|---|
| author | Amilton Dos Santos-Júnior Taciane Barbosa Henriques Maricilda Palandi de Mello Osmar Henrique Della Torre Lúcia Arisaka Paes Adriana Perez Ferreira-Neto Letícia Esposito Sewaybricker Thiago Salum Fontana Eloisa Helena Rubello Valler Celeri Gil Guerra-Júnior Paulo Dalgalarrondo |
| author_facet | Amilton Dos Santos-Júnior Taciane Barbosa Henriques Maricilda Palandi de Mello Osmar Henrique Della Torre Lúcia Arisaka Paes Adriana Perez Ferreira-Neto Letícia Esposito Sewaybricker Thiago Salum Fontana Eloisa Helena Rubello Valler Celeri Gil Guerra-Júnior Paulo Dalgalarrondo |
| author_sort | Amilton Dos Santos-Júnior |
| collection | DOAJ |
| description | Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations. |
| format | Article |
| id | doaj-art-d7b533f9b895486ca4b4a8c5523f52cd |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-d7b533f9b895486ca4b4a8c5523f52cd2025-02-03T05:58:07ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/58724235872423Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and AdolescentsAmilton Dos Santos-Júnior0Taciane Barbosa Henriques1Maricilda Palandi de Mello2Osmar Henrique Della Torre3Lúcia Arisaka Paes4Adriana Perez Ferreira-Neto5Letícia Esposito Sewaybricker6Thiago Salum Fontana7Eloisa Helena Rubello Valler Celeri8Gil Guerra-Júnior9Paulo Dalgalarrondo10Department of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilLaboratory of Human Genetics, Center for Molecular Biology and Genetic Engineering (CBMEG), Unicamp, 13083-875 Campinas, SP, BrazilLaboratory of Human Genetics, Center for Molecular Biology and Genetic Engineering (CBMEG), Unicamp, 13083-875 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilGrowth and Development Laboratory, Center for Investigation in Pediatrics (CIPED), FCM-Unicamp, 13083-887 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilGrowth and Development Laboratory, Center for Investigation in Pediatrics (CIPED), FCM-Unicamp, 13083-887 Campinas, SP, BrazilDepartment of Psychiatry, School of Medical Sciences (FCM), State University of Campinas (Unicamp), 13083-887 Campinas, SP, BrazilObjective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations.http://dx.doi.org/10.1155/2016/5872423 |
| spellingShingle | Amilton Dos Santos-Júnior Taciane Barbosa Henriques Maricilda Palandi de Mello Osmar Henrique Della Torre Lúcia Arisaka Paes Adriana Perez Ferreira-Neto Letícia Esposito Sewaybricker Thiago Salum Fontana Eloisa Helena Rubello Valler Celeri Gil Guerra-Júnior Paulo Dalgalarrondo Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents International Journal of Endocrinology |
| title | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| title_full | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| title_fullStr | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| title_full_unstemmed | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| title_short | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
| title_sort | pharmacogenetics of risperidone and cardiovascular risk in children and adolescents |
| url | http://dx.doi.org/10.1155/2016/5872423 |
| work_keys_str_mv | AT amiltondossantosjunior pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT tacianebarbosahenriques pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT maricildapalandidemello pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT osmarhenriquedellatorre pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT luciaarisakapaes pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT adrianaperezferreiraneto pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT leticiaespositosewaybricker pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT thiagosalumfontana pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT eloisahelenarubellovallerceleri pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT gilguerrajunior pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT paulodalgalarrondo pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents |